POSTER_MBA, CLIA, EIA Borrelia_Comparison of methods for determining Borrelia antibodies.pdf
(pdf - 2117 kB)
POSTER_MBA multiplex diagnostics of antinuclear antibodies in microtiter plate format (Czech republic).pdf
(pdf - 450 kB)
POSTER_MBA ANA_A comparative study of MBA with conventional routine methods for the detection of antibodies associated with SLE and Scl in Czech population (Czech Republic, 2024).pdf
(pdf - 673 kB)
POSTER_MBA ANA_Assessment of the possible role of Micro-Array testing in the diagnostics flow-chart of a specialist referral laboratory for autoimmune diseases (Italy, 2024).pdf
(pdf - 291 kB)
POSTER_MBA ANA_ICAP classification patterns under magnifying glass of multiplex antibodies detections (Romania,2024).pdf
(pdf - 545 kB)
POSTER_Immunological imprinting by seasonal coronaviruses and previous herpesvirus infections in long covid patients (Netherlands, 2024).pdf
(pdf - 2673 kB)
POSTER_Enhanced detection of antinuclear antiodies in IIM - A comparative study of MBA and conventional methods.pdf
(pdf - 219 kB)
POSTER_MBA Borrelia_Microarray immunoblot in the diagnosis of pediatric Lyme neuroborreliosis (Czech Rebublic).pdf
(pdf - 2022 kB)
POSTER_MBA Borrelia_(Hungarian).pdf
(pdf - 1397 kB)
SARS-CoV-2 in tumor tissue in glioblastoma patients (Poland, 2025).pdf
Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic.pdf
Granulocytic Anaplasmosis -underdiagnosed disease in veterinary and human medicine in Romania (Romania, 2025).pdf
Correlation between COVID-19 severity and previous exposure of patients to Borrelia spp. (Poland, 2022).pdf
Antibodies to NCP, RBD and S2 SARS-CoV-2 in Vaccinated and Unvaccinated HealthcareWorkers (Poland, 2022).pdf
Clinical outcomes, immunogenicity, and safety of BNT162b22 Vaccine in Primary Antibody Deficiency (Czech Republic, 2022).pdf
COVID-19 in a patient with neuroendocrine pancreatic cancer - Case report (Poland, 2022).pdf
Dynamics of anti-SARS-CoV-2 seroconversion in individual patients at the population level (Poland, 2022).pdf
Hidden fraction of Polish population immumne to SARS-CoV-2 in May 2021 (Poland, 2022).pdf
Immune response to COVID-19 mRNA Vaccine - A Pilot Study (Poland, 2021).pdf
Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF patients (Czech Republic, 2021).pdf
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients (Czech Republic, 2021).pdf
Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein-specific T cells in Lung Transplant Recipients (Czech Republic, 2021).pdf
Dynamics and correlation with commercial serologic tests (Belgium, 2021).pdf
Relationship between Humoral Response in COVID-19 and Seasonal Influenza Vaccination (Poland, 2022).pdf
SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors (Czech Republic, 2021).pdf
A systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients (USA, 2022).pdf
Antibody Tests May Be Widely Accepted (China, 2022).pdf
Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients (Poland, 2023).pdf
IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients (Poland, 2022).pdf
Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Diseas (Czech Republic, 2023).pdf
SARS antibody NCP, RBD and S2 in women vaccinated with booster Pfizer Vaccine and infected in meantime with SARS-CoV-2 (Poland, 2022).pdf
(pdf - 376 kB)
SARS-CoV-2 specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressive patients (Czech Republic, 2022).pdf
SARS-CoV-2 Viral Load Assessment in Lung Transplantation (Czech Republic, 2021).pdf
Influenza vaccination as a prognostic factor of humoral IgA responses to SARS-CoV-2 infection (MBA_2024, Poland).pdf
Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant (Poland, 2022).pdf
Association between the Seroprevalence of Antibodies against Seasonal coronaviruses and SARS-CoV-2 (Poland, 2023).pdf
SARS Antibodies NCP, RBD and S2 in Women Vaccinated with Booster Pfizer Vaccine and infected in meantime with SARS-CoV-2 (Poland, 2022).pdf
Humoral_response_after_breakthrough_SARS-CoV-2_inf.pdf
Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes (Poland, 2024).pdf
Dynamics of the level of anit-SARS antibodies within a year after three vaccinations of patients with prostate cancer (Poland, 2025).pdf
Dynamics of the level of anit-SARS antibodies within a year after three vaccinations of patients with prostate cancer (Poland, 2025).pdf
Can the Epstein–Barr Virus Play a Role in the Development of Prostate Cancer? (Poland, 2024).pdf
Serum Anti-Zta and Anti-LMP1 Antibodies in Oropharyngeal Cancer Related to Epstein–Barr Virus—Diagnostic Usefulness (Poland, 2024).pdf
Could MMP3 and MMP9 serve as biomarkers in EBV-related oropharyngeal cancer (MBA_2024, Poland).pdf
Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status (Poland, 2024).pdf
JC Polyoma virus in prostate cancer - friend or Foe (Poland, 2025).pdf
The impact of type 2 diabetes on selected clinical parameters and serological markers in patients with EBV-related oropharyngeal cancer (Poland, 2025).pdf
The impact of type 2 diabetes on selected clinical parameters and serological markers in patients with EBV-related oropharyngeal cancer (Poland, 2025).pdf
TestLine publications_30.5.2025.pdf
(pdf - 722 kB)